Graft Versus Host Disease (GVHD) Global Clinical Trials Review, H2, 2017

2017-08-30
Price :
Published : Aug-2017
No. of Pages : 570
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Report Guidance 6
GlobalData Clinical Trials Report Coverage 7
Clinical Trials by Region 8
Clinical Trials and Average Enrollment by Country 9
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 12
Top Five Countries Contributing to Clinical Trials in Europe 13
Top Countries Contributing to Clinical Trials in North America 14
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 15
Top Countries Contributing to Clinical Trials in Central and South America 16
Clinical Trials by G7 Countries: Proportion of Graft Versus Host Disease (GVHD) to Immunology Clinical Trials 17
Clinical Trials by Phase in G7 Countries 18
Clinical Trials in G7 Countries by Trial Status 19
Clinical Trials by E7 Countries: Proportion of Graft Versus Host Disease (GVHD) to Immunology Clinical Trials 20
Clinical Trials by Phase in E7 Countries 21
Clinical Trials in E7 Countries by Trial Status 22
Clinical Trials by Phase 23
In Progress Trials by Phase 24
Clinical Trials by Trial Status 25
Clinical Trials by End Point Status 26
Subjects Recruited Over a Period of Time 27
Clinical Trials by Sponsor Type 28
Prominent Sponsors 29
Top Companies Participating in Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials 31
Prominent Drugs 32
Latest Clinical Trials News on Graft Versus Host Disease (GVHD) 33
Aug 14, 2017: Kalytera Submits Phase 2 Study Protocol to IRBs for Cannabidiol in the Prevention of Graft versus Host Disease 33
Jul 25, 2017: Kadmon Announces Supplemental Interim Phase 2 Data of KD025 in Chronic Graft-Versus-Host Disease 33
Jul 20, 2017: Incyte Announces First Patient Treated in Phase 3 Clinical Trial of Itacitinib for Acute Graft-Versus-Host Disease 33
Jul 11, 2017: Kadmon Announces Interim Phase 2 Data of KD025 in Chronic Graft-Versus-Host Disease 34
Jul 05, 2017: FDA Meeting Provides Clear Path for Cynata US Development Plans 34
Jun 26, 2017: Neovii: Long-term Outcomes After Standard Graft-Versus-Host Disease Prophylaxis in Hemopoietic Cell Transplantation From Matched Unrelated Donors Strongly Support the Use of Grafalon (Anti-Human-T-Lymphocyte Immunoglobulin) as Standard Therapy 35
Jun 24, 2017: European Hematology Association: Multicenter Open-label Phase 2 Study of ibrutinib in Chronic Graft Versus Host Disease (cGVHD) After Failure of Corticosteroids 35
Jun 23, 2017: Kadmon to Present Interim Data on KD025 in Chronic Graft-Versus-Host Disease at R&D Day 35
Jun 14, 2017: Alpine Immune Sciences Announces Presentation of Preclinical Data Showing Potency of Its First-Generation Dual ICOS and CD28 Antagonist vIgDs in an Animal Model 36
Clinical Trial Profile Snapshots 37
Appendix 568
Abbreviations 568
Definitions 568
Research Methodology 569
Secondary Research 569
About GlobalData 570
Contact Us 570
Source 570

List of Tables
Graft Versus Host Disease (GVHD) Therapeutics, Global, Clinical Trials by Region, 2017* 8
Graft Versus Host Disease (GVHD) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 10
Graft Versus Host Disease (GVHD) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 11
Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 12
Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 13
Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials, North America, Top Countries, 2017* 14
Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2017* 15
Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials, Central and South America, Top Countries, 2017* 16
Proportion of Graft Versus Host Disease (GVHD) to Immunology Clinical Trials, G7 Countries (%), 2017* 17
Graft Versus Host Disease (GVHD) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 18
Graft Versus Host Disease (GVHD) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 19
Proportion of Graft Versus Host Disease (GVHD) to Immunology Clinical Trials, E7 Countries (%), 2017* 20
Graft Versus Host Disease (GVHD) Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 21
Graft Versus Host Disease (GVHD) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 22
Graft Versus Host Disease (GVHD) Therapeutics, Global, Clinical Trials by Phase, 2017* 23
Graft Versus Host Disease (GVHD) Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 24
Graft Versus Host Disease (GVHD) Therapeutics, Global, Clinical Trials by Trial Status, 2017* 25
Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials, Global, by End Point Status, 2017* 26
Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 27
Graft Versus Host Disease (GVHD) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 28
Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 30
Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 31
Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 32

List of Figures
Graft Versus Host Disease (GVHD) Therapeutics, Global, Clinical Trials by Region (%), 2017* 8
Graft Versus Host Disease (GVHD) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 9
Graft Versus Host Disease (GVHD) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 11
Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017* 12
Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 13
Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 14
Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2017* 15
Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2017* 16
Proportion of Graft Versus Host Disease (GVHD) to Immunology Clinical Trials, G7 Countries (%), 2017* 17
Graft Versus Host Disease (GVHD) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 18
Graft Versus Host Disease (GVHD) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 19
Proportion of Graft Versus Host Disease (GVHD) to Immunology Clinical Trials, E7 Countries (%), 2017* 20
Graft Versus Host Disease (GVHD) Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 21
Graft Versus Host Disease (GVHD) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 22
Graft Versus Host Disease (GVHD) Therapeutics, Global, Clinical Trials by Phase (%), 2017* 23
Graft Versus Host Disease (GVHD) Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 24
Graft Versus Host Disease (GVHD) Therapeutics, Global, Clinical Trials by Trial Status, 2017* 25
Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials, Global, by End Point Status, 2017* 26
Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 27
Graft Versus Host Disease (GVHD) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 28
Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 29
Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 31
Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 32
GlobalData Methodology 569
Filed in: Pharmaceutical
Publisher : GlobalData